false
0001828318
0001828318
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): November 18, 2026
Enovix Corporation

(Exact Name of Registrant
as Specified in Its Charter)
| Delaware |
|
001-39753 |
|
85-3174357 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
3501 W Warren Avenue
Fremont, California |
|
94538 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s
Telephone Number, Including Area Code: (510) 695-2350
Not Applicable
(Former Name or Former
Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
ENVX |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
As
previously disclosed, on October 28, 2026, Enovix Corporation, a Delaware corporation (the “Company”), announced that the
Board of Directors of the Company declared a distribution (the “Warrant Distribution”) to the holders of record of the Company’s
common stock, par value $0.0001 per share (the “Common Stock”), in the form of warrants to purchase shares of Common Stock
(the “Warrants”). The Warrants were issued on the terms and conditions described in the Warrant Agreement (as defined below
and attached as an exhibit hereto) and are being distributed on November 18, 2026, to the holders of record of Common Stock as of the
close of business on November 13, 2026 (the “Record Date”).
Pursuant
to the terms of the Warrant Agreement, dated as of November 18, 2026, between the Company, Computershare Inc., a Delaware corporation,
and its affiliate, Computershare Trust Company, N.A., as Warrant Agent (the “Warrant Agent”) (such agreement, the “Warrant
Agreement”), each holder of record of Common Stock as of the Record Date will receive one Warrant for every four shares of Common
Stock (rounded down to the nearest whole number for any fractional Warrant). Holders (“other eligible recipients”) of our
3.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and the Company’s 4.75% Convertible Senior Notes due
2030 (collectively with the 2028 Notes, the “Convertible Notes”) will also receive, at the same time and on the same terms
as holders of Common Stock, Warrants without having to convert such other eligible recipient’s Convertible Notes as
if each such holder of Convertible Notes held a number of shares of Common Stock equal to the product of (i) the conversion rate applicable
to the Convertible Notes in effect on the Record Date, and (ii) the aggregate principal amount (expressed in thousands) of Convertible
Notes held by such noteholder on such date.
Each
Warrant will entitle the holder to purchase, at the holder’s sole and exclusive election, at an exercise price of $3.00 per Warrant
(the “Warrant Exercise Price”), one share of Common Stock payable in cash. The
Warrants may also be exercised, at the election of the holder, by delivery of certain issued and outstanding notes that may be designated
by the Company from time to time pursuant to the terms of the Warrant Agreement (the “Designated Notes”) by delivering an
amount equal to $1,000 principal amount of Designated Notes to exercise up to 333 Warrants (subject to certain adjustments). The
Company has initially designated the 2028 Notes as Designated Notes.
Unless
the Early Expiration Price Condition (defined below) is met, the Warrants will expire and cease to be exercisable at 5:00 p.m. New York
City time on the date (the “Expiration Date”) which is (i) April 28, 2028 or (ii) if the Early Expiration Price Condition
occurs, the Early Expiration Date, where “Early Expiration Date” means either (x) the first Scheduled Trading Day (defined
below) immediately following the Early Expiration Price Condition Date (defined below) (subject to the terms of the Warrant Agreement)
(the “Scheduled Early Expiration Date”) or (y) if the Company elects to set an Alternate Early Expiration Date (defined below),
such Alternate Early Expiration Date.
Upon
the occurrence of the first 30 consecutive Trading Day (defined below) period (the “Reference Period”) that includes 20
Qualifying Trading Days (defined below) (whether or not consecutive) the first of which 20 Qualifying Trading Days must fall on or
after the first Trading Day immediately following the distribution date of the Warrants (the “Early Expiration Price
Condition”, and the last of such 20 Qualifying Trading Days (whether or not consecutive) to occur, the “Early Expiration
Price Condition Date”), the Expiration Date will automatically accelerate to the Scheduled Early Expiration Date, unless the
Company sets an Alternate Early Expiration Date (defined below) in accordance with the provisions described below and as further
described in the Warrant Agreement, in which case the Early Expiration Date will be such Alternate Early Expiration Date. In the
event of an early expiration of the Warrants, Warrants will be exercisable until 5:00 p.m. New York City time on the Early
Expiration Date. If the Early Expiration Price Condition occurs, the Company will make a public announcement by issuance of a press
release to that effect as promptly as practicable after market close on the Early Expiration Price Condition Date setting forth the
Early Expiration Date or an Alternate Early Expiration Date. Subject to applicable laws and regulations and the terms of the Warrant
Agreement, including the occurrence of the Early Expiration Price Condition or the Additional Price Conditions (defined below), the
Warrants may be exercised at any time starting on the date of issuance until 5:00 p.m. New York City time on the Expiration
Date.
The Company may, in its
sole discretion, elect to set the Early Expiration Date on a Scheduled Trading Day falling after the Scheduled Early Expiration Date
(such date, an “Alternate Early Expiration Date”). In order to exercise the right to set an Alternate Early Expiration
Date, the Company shall, no later than the fifth Qualifying Trading Day (whether or not consecutive) occurring in any 20 consecutive
Trading Day period ending on or before the next following Early Expiration Price Condition Date (if any), make a public announcement
by issuance of a press release that the Company is reserving the right to set an Alternate Early Expiration Date in the event the
Early Expiration Price Condition does occur. If the Company sets an Alternate Early Expiration Date, the expiration of the Warrants
on such Alternate Early Expiration Date shall be conditioned on (x) in respect of each of the two consecutive Scheduled Trading Days
immediately preceding such Alternate Early Expiration Date, no Market Disruption Event (as defined in the Warrant Agreement)
occurring and (y) the Daily VWAP (defined below) on each of such two consecutive Scheduled Trading Days immediately preceding such
Alternate Early Expiration Date being at least equal to the quotient obtained by dividing the Warrant Exercise Price by the
then-current Warrant Exercise Rate (as defined in the Warrant Agreement) (the “Additional Price Conditions”). As
promptly as practicable after close on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date, the
Company will make a public announcement by issuance of a press release as to whether the Additional Price Conditions are met. The
Company may, in its sole discretion, postpone such Alternate Early Expiration Date to a new Alternate Early Expiration Date (which,
for the avoidance of doubt, shall be conditional upon the Additional Price Conditions in respect of the Alternate Early Expiration
Date so postponed). The Company may, in its sole discretion, postpone further (on one or more occasions) such Alternate Early
Expiration Date of the Warrants to a new Alternate Early Expiration Date (which, for the avoidance of doubt, shall be conditional
upon the Additional Price Conditions with respect to the Alternate Early Expiration Date as so postponed). The Company will make a
public announcement of any such postponement by issuance of a press release as promptly as practicable after the close of regular
market hours of Nasdaq on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date to be so postponed. If
the Additional Price Conditions are not met as to an Alternate Early Expiration Date specified by the Company, unless the Company
sets a new Alternate Early Expiration Date as set forth in the preceding paragraph (an “Alternate Early Expiration Date
Annulment”), the Expiration Date will remain April 28, 2028 unless another Early Expiration Price Condition Date subsequently
occurs. The definitions of Early Expiration Price Condition, Early Expiration Price Condition Date and Reference Period are subject
to appropriate adjustment as set forth in the Warrant Agreement in the event of an Alternate Early Expiration Date Annulment.
All or any part of the Warrants
may be exercised prior to 5:00 p.m. New York City time on the Expiration Date (as it may be adjusted) by delivering to the Warrant Agent
a duly executed notice of election and the Warrants being exercised, and payment of the Warrant Exercise Price in cash or, if there are
Designated Notes, by delivery of Designated Notes.
For the purposes of the foregoing,
“Daily VWAP” of a share of Common Stock (or a Warrant or other security) on any date of determination means (i) in the case
of a share of Common Stock, for any day on which trading in the Common Stock generally occurs on the Nasdaq Global Select Market (the
“Exchange”) (or, if the Common Stock is not listed on the Exchange, the U.S. national or regional securities exchange or association
or over-the-counter market that is the primary market for the trading of the Common Stock on such day), the per-share volume-weighted
average price in the consolidated tape system during regular market hours as displayed under the headings “Calculation: Bloomberg”
and “VWAP” on Bloomberg page “ENVX US Equity AQR” (or its equivalent successor if such page or setting is not
available) in respect of such day, (ii) in the case of a Warrant, for any day on which trading in the Warrant generally occurs on the
Exchange (or, if the Warrant is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter
market that is the primary market for the trading of the Warrants on such day), the per-warrant volume-weighted average price in the consolidated
tape system during regular market hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on
Bloomberg page “ENVXW US Equity AQR” (or its equivalent successor if such page is not available) in respect of such day, and
(iii) in the case of any other security, for any day on which trading in such security generally occurs on the Exchange (or, if the security
is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the
primary market for the trading of such security on such day), the per-share volume-weighted average price in the consolidated tape system
during regular market hours as displayed on Bloomberg page “AQR” for such security in respect of such day. If such information
is not so available for the Common Stock or such Warrant or other security, the Daily VWAP on such date shall be the last reported sale
price for the Common Stock or such Warrant or other security on such day.
A “Trading Day”
for the purposes of the foregoing definition means a day on which the Common Stock (or Warrant or other security, as the case may be)
(i) at the close of regular way trading (not including after-hours or extended market trading) is not suspended from trading on the Exchange
or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, any U.S. national or regional
securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant
or such other security, as the case may be) at the close of business, and (ii) has traded at least once regular way on the Exchange or,
if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, such other U.S. national securities
exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such
other security, as the case may be); provided that if the Common Stock (or Warrant or such other security, as the case may be) is not
so listed or traded, “Trading Day” means a Business Day (as defined in the Warrant Agreement).
A “Qualifying
Trading Day” for purposes of the foregoing means any S+W Trading Day (defined below) on which the Daily VWAP of the Common
Stock on such Trading Day is at least equal to the Early Expiration Trigger Price (defined below) in effect on the last day of the
Reference Period (subject to the conditions and limitations set forth in the Warrant Agreement). An “S+W Trading Day”
means any day which is a Trading Day for both the Common Stock and the Warrants.
A “Scheduled Trading
Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange on which the
Common Stock is listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, the principal market
on which the Common Stock is admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading
Day” means a Business Day.
The “Early Expiration
Trigger Price” is initially equal to $3.30, subject to certain adjustments.
The
number of shares of Common Stock issuable upon exercise of the Warrants is subject to certain anti-dilution adjustments, including for
stock dividends, splits, subdivisions, reclassifications and combinations, other distributions and spin-offs, and shareholder rights plans.
In addition, the Warrant Exercise Rate may be voluntarily increased by the Company from time to time.
The
Warrants are expected to commence trading on the Nasdaq Stock Market LLC under the ticker “ENVXW” on November 19, 2026.
The
foregoing description of the Warrants and the Warrant Agreement is only a summary and is qualified in its entirety by reference to the
complete description of the terms of the Warrants set forth in the Warrant Agreement (including the Form of Warrant attached thereto),
which is filed as an exhibit to this Form 8-K. In connection with the Warrant Distribution, the Company is filing a prospectus supplement,
dated November 18, 2026, pursuant to the Company’s existing shelf registration statement on Form S-3, declared effective on November
9, 2026, registering up to $500,000,000 of shares of Common Stock, including the shares of Common Stock to be issued upon exercise of
the Warrants, under the Securities Act of 1933, as amended (the “Securities Act”).
Item 7.01 Regulation FD Disclosure.
On
November 18, 2026, the “Company” issued a press release announcing the Warrant Distribution to its shareholders and other
eligible recipients as of the November 13, 2026 Record Date. The press release is attached as Exhibit 99.1 to this Form 8-K.
Also
on November 18, 2026, the Company posted a further FAQ regarding the Warrant Distribution to the Company’s website (the “FAQ”).
The FAQ is attached as Exhibit 99.2 to this Form 8-K. The Company previously announced the Warrant Distribution on October 28, 2026 and
published an initial set of questions and answers on its website, which was furnished as Exhibit 99.2 to the Company’s Form 8-K
filed on October 28, 2026.
The
information furnished in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of
that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as
expressly set forth by specific reference in such filing.
No Offer or Solicitation
This
communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. A Form 8-A registration statement and prospectus supplement describing the terms
of the Warrants were filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2026 and are available
on the SEC’s website located at http://www.sec.gov. Holders of Company common stock should read the prospectus supplement carefully,
including the Risk Factors section included and incorporated by reference therein. This communication contains a general summary of the
Warrants. Please read the Warrant Agreement as it contains important information about the terms of the Warrants.
Forward-Looking Statements
This
Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act
about the Company, the Warrants and the Warrant Distribution. Forward-looking statements generally relate to future events and can be
identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict,
should, would and similar expressions that convey uncertainty about future events or outcomes. Actual results and outcomes could differ
materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, those
risks and uncertainties and other potential factors set forth in the Company’s filings with the SEC, including in the “Risk
Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections
of the Company’s most recently filed annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that the
Company has filed, or that it will file, with the SEC. Any forward-looking statements made by the Company in this Form 8-K, including
any forward-looking statements made by the Company in any of the exhibits to this Form 8-K, speak only as of the date on which they are
made and subsequent events may cause these expectations to change. The Company disclaims any obligations to update or alter these forward-looking
statements in the future, whether as a result of new information, future events or otherwise, except as required by law.
Item 9.01 Financial Statements and Exhibits.
On
November 18, 2026, Arnold & Porter Kaye Scholer LLP delivered an opinion (the “Opinion”) to the Company in connection
with the Company’s issuance of up to 62,329,657 shares of Common Stock upon exercise of the Warrants. Such shares will be issued pursuant
to the Company’s shelf registration statement on Form S-3 (No. 333-299760) (the “Registration Statement”), which was
declared effective on November 9, 2026, including the prospectus, dated November 9, 2026, and the prospectus supplement, dated November
18, 2026, as the same may be amended or supplemented. The Opinion is being filed herewith as Exhibit 5.1, and thereby automatically incorporated
by reference into the Registration Statement, in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities
Act.
(d) Exhibits
| Exhibit
Number |
|
Description |
| 4.1 |
|
Warrant Agreement (including Form of Warrant), dated November 18, 2026, between the Company, Computershare Inc., a Delaware corporation, and Computershare Trust Company, N.A., as Warrant Agent. |
| 5.1 |
|
Opinion of Arnold & Porter Kaye Scholer LLP |
| 23.1 |
|
Consent of Arnold & Porter Kaye Scholer LLP (included in Exhibit 5.1). |
| 99.1 |
|
Press Release dated November 18, 2026 |
| 99.2 |
|
Warrant Dividend Distribution FAQ dated November 18, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
| |
Enovix Corporation |
| |
|
|
| Date: November 18, 2026 |
By: |
/s/ Ryan Benton |
| |
|
Ryan Benton
Interim Chief Executive Officer and Chief Financial Officer |
Exhibit 99.1
Enovix Distributes Dividend of Warrants to Stockholders
FREMONT, Calif., November 18, 2026 (GLOBE NEWSWIRE) — Enovix
Corporation (“Enovix” or the “Company,” Nasdaq: ENVX), a developer and manufacturer of advanced lithium-ion batteries,
today announced that it will distribute warrants to purchase Enovix common stock (“Warrants”) to its stockholders and certain
convertible noteholders on November 18, 2026 (the “Distribution Date”), in accordance with the previously declared stockholder
warrant dividend. As previously announced, each stockholder of record as of the close of business on November 13, 2026 (the “Record
Date”) will receive one (1) Warrant for every four (4) shares of Enovix common stock held, rounded down to the nearest whole Warrant.
“Our first warrant dividend in 2025 demonstrated the strong support
of our stockholders and their interest in participating directly in Enovix’s growth,” said Ryan Benton, Interim Chief Executive
Officer. “This distribution builds on that by giving investors another way to participate while helping us address our outstanding
debt by permitting Warrant exercises with the delivery of our 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”).
Accepting our 2028 Notes at face value as payment of the exercise price allows us to retire debt and preserve cash for the business, while
cash exercises provide additional funding that we could also apply toward retiring outstanding 2028 Notes and preserving flexibility to
support execution on our priorities.”
Warrant Terms
Eligibility: Stockholders must have purchased or held shares
no later than November 12, 2026 to be a stockholder of record as of the close of business on the November 13, 2026 Record Date and to
receive Warrants.
Convertible Noteholders: Holders of our 2028 Notes and our 4.75%
Convertible Senior Notes due 2030 (the “2030 Notes”) as of the Record Date will also receive Warrants on a pass-through basis,
as provided under the applicable indentures, at the same one-for-four ratio.
Receipt of Warrants: Eligible recipients do not need to take
any action or make any payment to receive their Warrants. Holders may exercise, hold or sell the Warrants. Holders whose securities are
held through an intermediary should contact that intermediary with questions about when the Warrants will appear in their accounts.
Cash Exercise Price: Each Warrant entitles the holder to purchase
one (1) share of Enovix common stock for $3.00 in cash, subject to adjustments and amendments under the warrant agreement.
Note Exercise Alternative: In lieu of cash, holders may exercise
333 Warrants by delivering $1,000 principal amount of 2028 Notes. Unless otherwise permitted by Enovix, the 2030 Notes may not be used
to exercise the Warrants.
Listing: The Warrants are expected to begin trading separately
from Enovix common stock on Nasdaq under the symbol ENVXW on November 19, 2026, subject to applicable approvals.
Scheduled Expiration: April 28, 2028, at 5:00 p.m. New York
City time, subject to early expiration and any extension under the warrant agreement.
Early Expiration Price Condition: This condition will be satisfied
if the daily volume-weighted average price (“VWAP”) of Enovix common stock equals or exceeds 110% of the then-applicable exercise
price, initially $3.30, on twenty (20) trading days within any thirty (30) consecutive trading-day period following issuance (the “Early
Expiration Price Condition”). The qualifying trading days need not be consecutive.
If the Early Expiration Price Condition is satisfied, the Warrants
will expire at 5:00 p.m. New York City time on the business day immediately following the final qualifying trading day, or a later date
selected by the Company in accordance with the warrant agreement. Enovix will announce the applicable expiration date by press release.
Exercise Using Cash or 2028 Notes
Beginning on the Distribution Date, holders may exercise their Warrants
using cash or 2028 Notes, subject to the warrant agreement.
The 2028 Notes are designated as eligible for exercise. The 2030 Notes
are not eligible and may not be delivered as payment. The Company may, in its discretion and subject to the notice requirements and other
terms of the warrant agreement, change the debt securities designated as eligible for exercise.
For cash exercises, each Warrant entitles the holder to purchase one
(1) share of Enovix common stock for $3.00. For exercises using 2028 Notes, holders may deliver $1,000 principal amount of 2028 Notes
for every 333 Warrants exercised and receive 333 shares. Note exercises must be submitted in whole multiples of this ratio, regardless
of the market price of the 2028 Notes.
For example, a holder delivering $20,000 principal amount of 2028 Notes
may exercise 6,660 Warrants and receive 6,660 shares of common stock.
The ability to exercise Warrants with 2028 Notes is available to any
investor holding 333 Warrants for each $1,000 principal amount of 2028 Notes delivered. Warrants may be acquired through the dividend
distribution or in the open market. Any investor may purchase additional Warrants in the market for exercise, and certain qualifying investors
may purchase additional 2028 Notes in market transactions.
Any 2028 Notes delivered and accepted for exercise of Warrants will
be cancelled, reducing Enovix’s outstanding debt and associated future interest obligations without requiring the Company to use
cash to repay that principal. Enovix will receive cash proceeds only from cash exercises of the Warrants. Any cash proceeds will be available
for general corporate purposes, including retiring 2028 Notes.
Exercise Procedures and Investor Resources
Holders whose Warrants or 2028 Notes are held through a broker, bank
or other intermediary should contact that intermediary regarding receipt of their Warrants, exercise instructions, permitted payment methods
and applicable deadlines.
The early expiration feature could substantially shorten the exercise
period. Holders should make arrangements with their intermediaries in advance, as intermediaries may impose deadlines earlier than the
Company’s deadline. Warrants not exercised before the applicable expiration deadline will expire without value.
The warrant agreement, prospectus supplement and related investor materials
describe the complete terms, including exercise procedures, adjustments to the Warrants, any exercise suspension provisions and the conditions
governing early expiration. The warrant agreement and related registration documents were filed with the U.S. Securities and Exchange
Commission (“SEC”) on November 18, 2026.
Additional information, including frequently asked questions, is available
on the Company’s Investor Relations website at https://ir.enovix.com.
Transaction Advisors
B. Dyson Capital Advisors is serving as exclusive advisor to the Company
on the structuring and distribution of the Warrants.
About Enovix
Enovix develops and manufactures advanced lithium-ion batteries, including
proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial and emerging edge-AI applications. Its proprietary
silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety
and reliability, supporting commercialization across consumer and industrial markets.
Enovix is headquartered in Silicon Valley with facilities in India,
South Korea and Malaysia, serving customers globally. For more information visit https://enovix.com and follow us on LinkedIn.
No Offer or Solicitation
This press release is for informational purposes only and shall not
constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The issuance of the Warrants has not been registered under the Securities
Act of 1933, as amended (the “Securities Act”), as the distribution of a Warrant for no consideration does not constitute
a sale of a security under Section 2(a)(3) of the Securities Act. A registration statement on Form 8-A describing the terms of the Warrants,
and a registration statement on Form S-3 and prospectus supplement relating to the issuance of shares of common stock upon exercise of
the Warrants, have been filed with the SEC, and are available on the SEC’s website at www.sec.gov. Holders should read these materials
carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary
of the Warrants. Please read the warrant agreement as it will contain important information about the terms of the Warrants.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or
operating performance and are identified by words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, possible,
potential, predict, project, should, will, would and similar expressions. Forward-looking statements in this press release include, but
are not limited to, statements regarding: the terms of the Warrants, including the ability to exercise Warrants using cash or 2028 Notes
and the scheduled expiration date and the Early Expiration Price Condition; the expected listing of the Warrants on Nasdaq and the existence
of a trading market for the Warrants; the number of Warrants that may be exercised and the payment method holders may select; and the
anticipated benefits to our balance sheet, interest obligations and liquidity of the Warrant distribution, as well as the anticipated
use of additional funding that may be raised through cash exercises of the Warrants to support execution on our priorities. These statements
are based on the current expectations of our management, are not predictions of actual performance, and actual results may differ materially
from the future results, performance or achievements expressed or implied by the forward-looking statements.
Risks, uncertainties and assumptions that could cause actual results
to differ materially from the results and events anticipated by such forward-looking statements include, but are not limited to: the possibility
that few or no Warrants are exercised, or that holders elect to exercise Warrants primarily for cash or primarily with 2028 Notes (or
the possibility that holders of 2028 Notes do not exercise Warrants by delivering 2028 Notes), such that the cash proceeds received or
the debt retired differ materially from our expectations; the possibility that the Warrants are not approved for listing on Nasdaq or
that an active trading market for the Warrants does not develop; the possibility that the Warrants expire without value, including because
holders are unable to complete an exercise before any accelerated expiration deadline; volatility in the trading price of our common stock
and the Warrants, including the possibility that the Early Expiration Price Condition is satisfied earlier or later than anticipated or
not at all; and other risks described in the disclosures contained in our filings with the SEC, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our annual report
on Form 10-K and quarterly reports on Form 10-Q, and other documents that we have filed, or will file, with the SEC. These documents are
available in the SEC Filings section of the Investor Relations page at https://ir.enovix.com and at www.sec.gov. It is not possible for
us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Accordingly,
you should not rely on any of the forward-looking statements. Any forward-looking statements in this press release speak only as of the
date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Contact
Monica Gould
Blueshirt Group
ir@enovix.com
Exhibit 99.2
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
● WARRANT
DIVIDEND DISTRIBUTION
Stockholder FAQ
Frequently asked questions about the Enovix warrant dividend
Enovix Corporation (Nasdaq: ENVX) is distributing warrants to its stockholders
and convertible noteholders at no cost. This FAQ explains what the warrants are, who receives them, how they can be exercised or sold,
and what to expect between the record date and expiration. It is a summary only; the warrant agreement and our filings with the Securities
and Exchange Commission (“SEC”) will govern.
● KEY
TERMS AT A GLANCE
| EXERCISE PRICE |
DISTRIBUTION RATIO |
| $3.00 per share |
1 warrant per 4 shares |
| |
|
| RECORD DATE |
DISTRIBUTION DATE |
| Friday, November 13, 2026 |
Wednesday, November 18, 2026 |
| |
|
| FIRST TRADING DAY |
NASDAQ TICKER |
| Thursday, November 19, 2026 |
ENVXW |
| |
|
| EXPIRATION DATE |
EARLY EXPIRATION TRIGGER |
| April 28, 2028 |
$3.30 VWAP, 20 of 30 trading days |
● IN
THIS DOCUMENT
| 01 The Basics |
|
02 How This Distribution Compares with 2025 |
|
03 Receiving Your Warrants |
| |
|
|
|
|
| 04 Exercise Price, Expiration and Early Expiration |
|
05 Exercising Your Warrants |
|
06 Trading the Warrants |
| |
|
|
|
|
| 07 Why This Structure |
|
08 Tax Considerations |
|
09 Other Questions |
01
THE BASICS
What is a Warrant?
A warrant is an option to buy common shares issued directly by a company.
Like any option, it gives the holder the right, but not the obligation, to purchase a share of common stock at a specified price (called
the “exercise price”) before the warrant expires.
What is a Warrant Dividend?
A warrant dividend is the process of distributing warrants on a pro
rata basis to our existing stockholders and convertible noteholders.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 1 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
Why is Enovix issuing these Warrants?
Enovix believes that a warrant dividend distribution is a stockholder-aligned
approach to strengthening its balance sheet while giving existing stockholders and noteholders the opportunity to participate in the related
equity issuance. Recipients can choose to exercise, hold or sell their warrants.
Building on the Company’s successful 2025 warrant dividend program,
this distribution adds the ability to exercise warrants using the Company’s 3.00% Convertible Senior Notes due 2028 (the “2028
Notes”) at face value. 2028 Notes surrendered upon exercise will be cancelled, reducing outstanding debt and associated future interest
obligations without requiring Enovix to use cash to repay that principal.
Cash exercises would provide additional liquidity for general corporate
purposes. Together, these alternatives provide a path to retiring the 2028 Notes and cash generation while preserving cash for the business
and putting the participation decision in each holder’s hands.
Who will receive the Warrants?
Holders of Enovix common stock as of the record date, November 13,
2026 (“stockholders”), will receive one warrant for every four (4) shares of common stock held, rounded down to the nearest
whole number. No fractional warrants will be issued.
Holders of the 2028 Notes and the 4.75% Convertible Senior Notes due
2030 (the “2030 Notes”) as of the record date (“noteholders”) will also receive warrants on an as-converted pass-through
basis in accordance with the terms of the governing agreements. As an example, holders of each $1,000 face amount of 2028 Notes will receive
approximately 16 warrants, and holders of each $1,000 face amount of the 2030 Notes will receive approximately 22 warrants, in each case
rounded down to the nearest whole number for any fractional warrant. No fractional warrants will be issued. Given this pass-through, the
warrant distribution will not trigger a further adjustment to the conversion rate for the convertible notes.
When will the Warrants be distributed?
The Company expects to distribute the warrants to stockholders and
noteholders on or about November 18, 2026 (the “distribution date”).
How many Warrants will be issued in total?
Including the effect of the Company’s repurchase and retirement
of $128.0 million in aggregate principal amount of the 2030 Notes completed in October 2026, approximately 62.3 million warrants will
be issued. This includes around 54.4 million warrants to common stockholders and an additional 7.9 million warrants to the noteholders,
in accordance with the terms of those securities.
How much will be raised if all Warrants are exercised?
If all 62.3 million warrants are exercised
at the $3.00 per share exercise price, Enovix would receive aggregate exercise consideration of approximately $169.1
million (excluding warrants held by our directors and executive officers), in a combination of cash and 2028 Notes surrendered at
face value. The actual amount of proceeds Enovix can receive will depend on the number of warrants ultimately exercised (which will
depend on, among other factors, the trading price of our common stock), the payment method selected by holders, and applicable
transaction costs.
What do I have to do to receive the Warrants?
You must be an eligible stockholder or noteholder as of the record
date to participate in the warrant distribution. The warrants will be issued without any action required by our equity holders and without
any payment of cash or other consideration.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 2 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
If you hold shares or convertible notes through a brokerage account,
bank, or financial institution and are a holder in street name, contact your broker for further information. If your shares are held in
a registered account with Enovix’s transfer agent, contact Client Services at Computershare Trust Company, N.A.
What happens to fractional warrants?
Fractional warrants will not be issued or distributed. If a holder
would otherwise be entitled to receive a fractional warrant, the total number of warrants issued to that holder will be rounded down to
the nearest whole warrant. As a result, stockholders whose shareholdings are not evenly divisible by four will receive only whole warrants.
For example, a stockholder owning 1, 100, or 145 shares of common stock would receive 0, 25, and 36 warrants, respectively.
Is management participating in the distribution?
All stockholders of record, including management stockholders, as of
the November 13, 2026 record date are eligible to receive this distribution; however, our directors and executive officers will only realize value on the warrants (on a net exercise basis) if the warrants are
in the money on the expiration date; and our directors and executive officers may not otherwise exercise, sell or transfer the warrants.
02
HOW THIS DISTRIBUTION COMPARES WITH 2025
How is this warrant distribution different from Enovix’s 2025
distribution?
This distribution builds on the success of our 2025 program with an
added benefit: holders can exercise using cash or 2028 Notes at face value. The warrants can therefore do more than raise capital. They
can also retire debt and reduce future interest obligations while keeping cash available for the business.
For stockholders, this combines the same opportunity to participate
in Enovix’s future growth with the potential benefit of a stronger balance sheet. Holders retain the choice to exercise, hold or
sell their warrants, with an additional way to fund their participation.
What were the results of the 2025 warrant dividend program?
Approximately 26.5 million warrants were exercised, generating approximately
$232.1 million in gross proceeds. The program concluded on August 29, 2025, when all remaining warrants were either exercised or expired.
The program demonstrated substantial investor participation and provided
additional capital to support Fab2 scale-up and general corporate purposes.
Why is Enovix undertaking another warrant distribution?
Enovix held approximately $512 million in cash, cash equivalents and
investments, including restricted cash, as of October 4, 2026. This distribution gives us an opportunity to build on that liquidity by
reducing outstanding debt and future interest obligations while keeping cash available to execute our business plans.
Following the strong investor participation in our 2025 program, we
are again putting the opportunity to participate directly in existing stockholders’ and noteholders’ hands. The pro rata distribution
gives stockholders the opportunity to maintain their proportional ownership on a fully-diluted basis by exercising their warrants if they
choose to do so. This distribution also adds the ability to exercise using 2028 Notes at face value, which aligns with the stockholder
opportunity to create a stronger balance sheet for the Company.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 3 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
How would this distribution reduce debt, raise cash and support
the Company’s business?
Warrants exercised using 2028 Notes would retire the surrendered principal
and reduce associated future interest obligations without requiring Enovix to use cash to repay that principal. Enovix would receive no
cash proceeds from those exercises.
Warrants exercised for cash would provide additional liquidity for
general corporate purposes, including a new source of funding for increasing the Company’s Korean drone battery manufacturing capacity
without drawing on existing cash. Together, these payment methods give the Company a path to reduce debt and raise capital while preserving
cash for business execution. The amount of debt retired and cash raised will depend on the number of warrants exercised and the payment
methods selected by holders.
How much debt could Enovix retire if warrants are exercised using
2028 Notes?
The aggregate exercise price of all warrants being distributed (approximately
$169.1 million) is approximately equal to the $172.5 million principal amount of 2028 Notes currently outstanding. If holders exercise
a sufficient number of warrants using 2028 Notes, most of the $172.5 million of 2028 Notes could be retired. The actual amount retired
will depend on how many warrants are exercised and whether holders choose to pay with cash or 2028 Notes.
03
RECEIVING YOUR WARRANTS
What’s the last day I can buy Enovix shares and still receive
the warrants?
To receive the warrant dividend, you must purchase Enovix shares no
later than the close of trading on November 12, 2026. Purchases made on or before November 12, 2026 should settle in time for you to be
a stockholder of record on November 13, 2026, the official record date, and you should be eligible to receive the warrants.
If you buy shares on November 13, 2026 or later, your purchase will
settle after the record date, and you will not receive any warrants. This is because November 13, 2026 is the ex-dividend date—the
first trading day on which the shares no longer carry the right to receive the warrant dividend.
I purchased my Enovix shares through an online brokerage account.
How will I receive my warrant notice or access the warrants?
Your broker is responsible for crediting your account with the warrants
if you held shares as of the record date. You should not need to take action to receive them, but processing times vary. Please contact
your broker directly for confirmation and additional information regarding timing and access to the warrants, including the mechanics
of warrant sales and exercises.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 4 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
My warrants are not showing up in my brokerage account. What should
I do?
Typically, your broker will be responsible for crediting your account
with warrants if you held shares as of the record date and such shares are not being pledged as collateral or loaned out. If your shares
are being pledged as collateral or loaned out, other mechanics may apply. In all cases you need to contact your broker directly for confirmation
and for any other information regarding timing and access to warrants, including the mechanics for warrant sales and exercises.
What happens if I hold my Enovix shares in a margin account and
the shares are on loan as of the November 13, 2026 record date?
If your Enovix shares are in a margin account, your broker may loan
out your shares – often without notifying you. This is standard practice for margin accounts. If your shares are loaned out at the
time of the warrant dividend record date, you are not considered the stockholder of record for purposes of receiving the warrant dividend
and will not receive any warrants directly from Enovix.
If your broker has loaned out your shares, instead of receiving actual
warrants from Enovix, your broker may instead post a placeholder entry in your account called an “in lieu of” credit. This
“in lieu of” warrant credit does not represent an exercisable warrant and you will not be able to exercise or trade your warrant
entry unless your broker takes steps to obtain the actual warrants for you, which is not guaranteed.
How do I ensure I receive the actual exercisable Enovix warrants
if I have a margin account?
Transfer your shares from a margin account to a cash account (or a
fully paid-for account) before the November 13, 2026 record date of the warrant dividend, and confirm with your broker that your shares
will be held in your name and not subject to lending or rehypothecation. Processing time varies by broker.
Do non-U.S. stockholders qualify to receive the warrant dividend?
Yes. There are no stated restrictions on international stockholders
receiving warrants. If you held Enovix common stock as of the record date through a brokerage account, you should receive the warrants
in your account. If you are a non-U.S. stockholder, you should contact your broker for jurisdiction-specific logistics, including with
regard to warrant sales and exercises.
I hold listed call options on Enovix common stock. Will I receive
the warrant dividend?
No. Only holders of record of our common shares or convertible notes
as of the November 13, 2026 record date will receive the warrant dividend. If you hold call options, you must exercise them and own the
shares before the record date to receive warrants.
Option holders should also review any notices from the Options Clearing
Corporation (“OCC”) to determine if there will be any adjustments to strike prices or deliverables. In connection with the
distribution, listed call options may receive an “NS” (non-standard) designation on the record date. NS-designated options
are not exercisable through automated systems and generally require manual exercise through your brokerage firm. Option holders should
contact their brokerage firm for details regarding exercise procedures and timing.
How are the warrants handled for shares held in a retirement account?
Warrants will be credited to your retirement brokerage account if you
held shares as of the record date. However, exercising or selling warrants from within a retirement account may be subject to additional
rules or restrictions. Please consult your retirement account custodian or tax advisor.
What if I hold a short position?
If you are short Enovix stock as of the record date, you will be required
on the distribution date to deliver the pro rata number of warrants to the lender of the shares you borrowed. As a result, market participants
with short positions may need to purchase warrants in the open market to meet this delivery obligation.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 5 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
04
EXERCISE PRICE, EXPIRATION AND EARLY EXPIRATION
What is the Exercise Price?
Each warrant entitles the holder to purchase one share of Enovix common
stock at an exercise price of $3.00. The exercise price may be paid in cash or by surrendering 2028 Notes at face value, as described
in Section 05.
What is the Expiration Date?
The warrants will expire on April 28, 2028, unless the Early Expiration
Price Condition is met.
What is the Early Expiration Price Condition?
If, during any 30 consecutive trading days, the volume-weighted average
price (VWAP) of Enovix common stock is at or above $3.30 for at least 20 of those days (not necessarily consecutive), then the warrants
will expire early — specifically at 5:00 p.m. New York City time on the business day immediately following that 30-day period or
such other date as the Company may elect in accordance with the warrant agreement.
Enovix will issue a press release if the Early Expiration Price Condition
is triggered.
When does the 20 out of 30-day VWAP measurement period for the Early
Expiration Price Condition begin?
The 20 out of 30-day VWAP measurement period can begin on the first
trading day after the distribution date. If Enovix shares are trading at or above $3.30 on that day and the VWAP meets the threshold,
that day counts as the first of the 20 qualifying days within the 30-trading-day window.
If the VWAP Early Expiration Price Condition is met, for example,
on the 20th qualifying day, when do the warrants expire?
The warrants will expire on the business day immediately following
the 20th qualifying trading day within any 30-day period, unless the Company announces an alternate expiration date in accordance with
the warrant agreement.
How will I know if the warrants are about to expire?
If the warrants are scheduled to expire, either on the final expiration
date or due to early expiration, Enovix will issue a public press release announcing the expiration date. This notice will be made available
as promptly as practicable and will include the exact date and time by which warrant exercises must be completed.
We encourage stockholders to monitor Enovix’s Investor Relations
website (https://ir.enovix.com) for news announcements and updates, as well as our filings with the SEC at www.sec.gov.
Can my broker impose an earlier deadline to exercise than Enovix’s
expiration time?
Yes. Your broker may require an earlier instruction deadline than the
stated expiration time of the warrants and may require you to submit notices by specific methods. We recommend confirming your broker’s
procedures, cut-offs and method of notice well in advance. Enovix also intends to issue a public press release reminder ahead of expiration.
What happens if the share price does not go up?
Holders may exercise their warrants at any time before expiration.
If the stock price does not reach or exceed the early expiration price of $3.30 for 20 out of 30 consecutive trading days, the warrants
will remain outstanding until their final expiration on April 28, 2028. If the stock never triggers early expiration, holders retain full
control over their participation through the end of the term.
What happens if I do not exercise the warrants before they expire?
If you do not sell or exercise your warrants by the applicable expiration
date, which may occur early as described above, such warrants will expire and have no value. Your rights under the warrants will lapse
with no further action required or penalty.
You can choose to hold the warrants until expiration, sell them, or
exercise them before expiration. If you take no action, the warrants simply expire. If other warrant holders exercise and new shares of
common stock are issued to them while you do not exercise your warrants, your percentage ownership in Enovix’s common stock will
decline.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 6 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
05
EXERCISING YOUR WARRANTS
When can I exercise my warrants?
You may exercise the warrants with cash at any time from the distribution
date until 5:00 p.m. New York City time on the April 28, 2028 expiration date, or one business day after the date on which the Early Expiration
Price Condition is reached (unless Enovix specifies an alternate expiration date as described in the warrant agreement).
You may also exercise the warrants with 2028 Notes at any time from
the distribution date until the Early Exercise Expiration Price Condition is reached, as described in the warrant agreement.
How do I exercise my warrants?
If you hold the warrants through a brokerage account, bank or financial
institution and are thus a holder in street name, you should contact your broker, bank or other financial institution intermediary for
information on how to exercise warrants. You may also contact Computershare Trust Company, N.A., the warrant agent, at 150 Royall Street,
Canton, MA 02021, Attention: Client Services, telephone 1-877-373-6374, if you have additional questions about the exercise process. You
can pay with cash or 2028 Notes using the following methods.
To exercise for cash, you may instruct
your broker to submit your exercise through the Depository Trust Company’s (“DTC”) WARR service and arrange payment
of the cash exercise price.
To exercise using 2028 Notes, you may
instruct your broker to submit your warrants and notes through DTC’s electronic system, known as ATOP. Computershare will review
the submissions, and accepted exercises will settle on a weekly schedule. Accrued interest on accepted notes, calculated through the applicable
allocation date, will be paid in cash along with your shares, based on the schedule in Exhibit C to the warrant agreement. Submission
deadlines and settlement dates will be specified in the applicable DTC event announcements.
You can also exercise directly with Computershare,
the warrant agent, using cash or 2028 Notes. For this method, you must submit a completed election to purchase warrant shares, included
in Exhibit A to the warrant agreement, and arrange the applicable payment and delivery of securities. Your broker can arrange the required
securities deliveries through DTC’s DWAC system, which allows securities to be transferred to and from the warrant agent. No separate
accrued-interest payment is made for notes surrendered through this method.
If you are a direct registration holder, to exercise your warrants,
you must provide payment to Computershare Trust Company, N.A. either (i) in United States dollars by certified or official bank check
or wire transfer of immediately available funds to an account designated by Enovix or (ii) by the surrender of 2028 Notes having a face
value, in each case, equal to $1,000 for every 333 warrants exercised. Such payment must specify the name of the holder and the number
of warrants exercised. You also are required to present the election to purchase warrant shares attached to the warrant.
If you have any questions or cannot locate your warrant statement,
please contact Computershare Trust Company, N.A., as warrant agent.
Please refer to the warrant agreement, including the section relating
to “exercise terms” and the form of election to purchase warrant shares exhibit to the warrant agreement, which will be filed
with the SEC together with the Form 8-A to register the warrants, at or prior to the distribution date.
How do I pay the exercise price, and how will the warrants be settled
upon exercise?
The exercise price of the warrants is $3.00. A warrant holder may exercise
their warrants at any time for cash, and exercises may be made with 2028 Notes, as will be specified under the terms in the warrant agreement.
A warrant holder who surrenders 2028 Notes will be credited the $1,000 face value of those notes against the exercise price of the warrants,
regardless of the notes’ trading price.
For purposes of payment of the exercise price, $1,000 principal amount
of 2028 Notes shall be deemed to be equal to the aggregate exercise price for 333 warrants. Note exercises will be calculated using this
fixed ratio, rather than by dividing the principal amount delivered by the cash exercise price, subject to adjustments provided in the
warrant agreement. Only after the payment of the exercise price will holders receive shares of the Company’s common stock.
For example, a holder who exercises 333,000
warrants and delivers $1,000,000 face value of 2028 Notes will receive 333,000 shares. Holders of 2028 Notes who are not also
stockholders of record may purchase additional warrants in the market in order to deliver a larger amount of their 2028 Notes to exercise warrants for shares of common stock.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 7 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
Can I purchase warrants or 2028 Notes in the open market to participate?
Yes. Holders of Enovix’s 2028 Notes may purchase additional warrants
in the open market and exercise them using their notes. Stockholders who receive warrants in the distribution may also purchase 2028 Notes
in the open market to pay the exercise price instead of cash. Other investors may purchase both warrants and 2028 Notes in the open market
and submit them for exercise to receive Enovix common shares, in accordance with the warrant terms and exercise procedures.
Which Enovix notes are eligible for exercise?
Effective on the distribution date, notes of the following series issued
by Enovix may be used to pay the exercise price:
| TITLE OF SERIES | |
CUSIP / ISIN | |
PRINCIPAL
AMOUNT
OUTSTANDING | | |
CONSIDERATION PER $1,000
PRINCIPAL AMOUNT SURRENDERED |
| 3.00% Convertible Senior Notes due 2028 | |
293594AC1 / US293594AC17 | |
$ | 172,500,000 | | |
Warrant exercise price valued at the aggregate principal amount of the notes surrendered (regardless of the then-current market value of such notes), excluding any accrued and unpaid interest. |
Enovix may add or remove the right to use a particular series of notes
to pay the exercise price, provided that Enovix will give at least 20 business days’ notice before removing a series of notes from
being eligible to pay the warrant exercise price. If we decide to add or remove notes, we will promptly make a public announcement, update
our website and the corresponding table to reflect the change.
What happens if I surrender more in principal amount of notes than
I exercise in warrants?
The principal amount of any 2028 Notes surrendered to exercise warrants
in excess of the exercise price shall be forfeited to Enovix and will not be refunded unless the excess is greater than $1,000, in which
case Enovix will return any notes in multiples of $1,000 principal amount pursuant to the terms of the warrant agreement.
If I use notes to pay for the exercise of the warrants, will I receive
accrued interest?
If your broker submits your warrants and 2028 Notes through DTC’s
ATOP system, accrued interest on the accepted notes, calculated through the applicable allocation date, will be paid in cash along with
your shares on the weekly settlement date. The amount will be determined using the accrued-interest schedule in Exhibit C to the warrant
agreement.
If you instead exercise directly with Computershare using the DWAC
process, you will not receive a separate accrued-interest payment.
For notes surrendered after the coupon record date and before the corresponding
coupon payment date, no separate accrued-interest payment will be made for the exercise. Instead, the normal coupon will be paid to the
holder entitled to it as of the record date, in accordance with the applicable indenture.
Please confirm with your broker which exercise method to use.
06
TRADING THE WARRANTS
Will the Warrants trade publicly?
Yes. The warrants are expected to be listed on Nasdaq under the ticker
symbol ENVXW and to begin trading on or about November 19, 2026, the first trading day after the distribution date.
Can I sell my Warrants?
Yes. The warrants are expected to be tradeable on Nasdaq. You can choose
to hold, exercise, or sell them based on your financial objectives. Your ability to sell the warrants will depend, in part, on whether
a trading market develops for the warrants.
07
WHY THIS STRUCTURE
Will this dilute my ownership?
There is no immediate dilution when we issue the warrants. New shares
will only be issued if warrants are exercised and the Company receives the exercise price, in cash or in 2028 Notes. Unlike a traditional
equity raise, this structure allows you to maintain your proportional ownership and avoid dilution by exercising your warrants.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 8 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
What will the Company use the proceeds for?
Enovix intends to use any cash proceeds from the exercise of the warrants
for general corporate purposes, including reducing existing debt. Exercise of warrants in exchange for 2028 Notes will not result in any
cash proceeds to Enovix but will reduce the amount of debt Enovix has outstanding and associated interest expense. In either event, we
expect this to be a deleveraging transaction.
Why is the Company using this structure instead of a traditional
equity raise?
The warrant dividend puts the opportunity to participate in the Company’s
equity issuance directly in the hands of existing stockholders and noteholders. Recipients receive warrants in proportion to their existing
holdings and can choose to exercise them, hold them or sell them to realize any available market value, without an obligation to invest
additional funds.
The warrants serve two purposes: cash exercises would raise additional
capital, while exercises using 2028 Notes at face value would retire outstanding debt and reduce associated future interest obligations
without requiring Enovix to use cash to repay that principal. This gives the Company a path to both cash generation and debt reduction
while preserving cash for the business and giving existing investors the opportunity to participate in its future growth.
Why would stockholders want this structure?
It gives our stockholders free optionality to choose what they want
to do. Those who believe in our strategy gain the right, without any obligation, to buy more stock at a fixed, attractive price in the
future. If we execute well, they benefit. If not, they’ve risked nothing. Holders also have the flexibility to sell their warrants
and realize immediate value. We’re putting choice and timing in our stockholders’ hands.
Stockholders will also benefit from Enovix’s reduced leverage
following the exercise of warrants with outstanding notes and from the Company’s increased cash position from warrants exercised
with cash.
Our goal is to scale responsibly while protecting stockholder interests.
This structure ensures capital is available when operational success justifies it, reinforcing long-term discipline and financial readiness,
without pressuring the Company to raise funds under suboptimal conditions.
Why would noteholders want this structure?
Noteholders benefit as their 2028 Notes may be used to exercise warrants
at the face value of the notes, regardless of the notes’ trading price. Upon exercise with the 2028 Notes, the leverage ratios of
the Company will improve.
08
TAX CONSIDERATIONS
What are the tax implications?
The U.S. federal income tax consequences of the warrant dividend are
complex and may vary based on each stockholder’s individual circumstances. Stockholders are encouraged to consult with their tax
advisor to understand how the distribution may affect their individual tax situation.
For U.S. taxpayers, how will the warrant exercise be treated for
tax purposes?
For U.S. taxpayers who receive warrants, this will generally not be
a taxable event. However, if you exercise the warrants and later sell the resulting shares, you may incur capital gains taxes. In the
event you exercise your warrants in exchange for shares, your cost basis for those shares will be the $3.00 exercise price, plus any transaction
costs incurred.
The U.S. federal income tax treatment of the warrant distribution may
vary based on an investor’s specific circumstances. Enovix does not provide tax advice. Investors are encouraged to consult their
tax advisor regarding the potential impact of the distribution.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 9 |
 |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
Additional details will be provided in the tax reporting section of
the prospectus supplement, which Enovix expects to file with the SEC on the distribution date.
09
OTHER QUESTIONS
Are there risks to me of the warrants?
Yes. Like any security, the warrants involve risks. For example, they
could expire with no value if not exercised, trading/liquidity may be limited, and early expiration can shorten the time to act. Please
review the “Risk Factors” in Enovix’s prospectus supplement that we intend to file in connection with the warrants and
our other filings with the SEC for a more detailed discussion.
Can Enovix change the terms of the warrants?
The procedures relating to any amendments or adjustments to the terms
of the warrants will be set forth in the warrant agreement.
Can I receive a copy of the full warrant agreement?
Yes. Enovix expects to file the full warrant agreement with the SEC
on or prior to the distribution date. It will be available via the SEC’s EDGAR system at www.sec.gov and on the Enovix Investor
Relations page at ir.enovix.com.
Where can I find more information?
More information will be available in our investor presentation and
our filings with the SEC. You may also contact Enovix Investor Relations at ir@enovix.com.
IMPORTANT INFORMATION
This document is provided for informational purposes only and is not
an offer to sell or a solicitation of an offer to buy any securities. The warrants and the shares of common stock issuable upon exercise
will be offered pursuant to a registration statement on Form S-3 and a prospectus supplement filed with the SEC. Investors should read
the prospectus supplement, the warrant agreement and Enovix’s other filings with the SEC, which contain important information, including
risk factors, before making any investment decision. Statements regarding expected dates, amounts and outcomes are forward-looking and
subject to change. Enovix does not provide tax, legal or investment advice; please consult your own advisors.
FORWARD-LOOKING STATEMENTS
This FAQ contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements regarding the expected record date, distribution date, listing
and expiration of the warrants; the number of warrants to be issued; the number of warrants that may be exercised and the payment methods
holders may select; the amount of cash raised or 2028 Notes retired; the expected benefits of the warrant dividend, including reduced
debt and interest expense; the anticipated use of proceeds; and the expected tax treatment of the distribution. These statements are based
on management’s current expectations and are not guarantees of future performance. Actual results may differ materially due to risks
and uncertainties, including the possibility that few or no warrants are exercised, that the distribution is delayed or modified, or that
the cash proceeds received or debt retired differ materially from our expectations; volatility in the trading price of our common stock
and warrants; and the other risks described in the “Risk Factors” sections of our annual report on Form 10-K, our quarterly
reports on Form 10-Q and the prospectus supplement relating to the warrants, each filed or to be filed with the SEC and available at https://ir.enovix.com
and www.sec.gov. Forward-looking statements speak only as of the date of this document, and Enovix undertakes no obligation to update
or revise them, whether as a result of new information, future events or otherwise.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 10 |